Blocking NFKappaB entirely in humans poses significant challenges and risks, as it is crucial for various cellular functions. While it is not feasible to inhibit NFKappaB throughout the entire body without severe consequences, targeted inhibition in specific organs may be possible. IkappaB, a known inhibitor of NFKappaB, has different forms that can potentially modulate its activity in certain tissues. However, achieving organ-specific inhibition is complex due to the need to interact with similar receptors, which complicates the development of precise treatments. Current research focuses on modifying protein structures to enhance receptor specificity, but this typically requires extensive in vitro studies before any human trials can be considered. The potential for organ-specific inhibition could lead to advancements in treating various medical conditions, but the implementation remains fraught with technical and safety challenges.
